OVERVIEW
Stocktwits Top 25 Week 13
Welcome to the Stocktwits Top 25 Newsletter for Week 13 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 13:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
S&P 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+1.44%) outperformed the S&P 500 index (+0.39%).
There were 5 major changes to the list this week.
Check out how the momentum meter has performed vs. the S&P 500 index.
STOCKTWITS EDGE
Elevate Your Trading Game 👀
Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (-0.85%) underperformed the Nasdaq 100 index (-0.46%).
There were 2 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+9.66%) outperformed the Russell 2000 index (+2.54%).
There were 3 major changes to the list this week.
Top Dawg Of The Week 🐶
The Top 25 lists' Top Dawg was Stoke Therapeutics, which rallied 114.29%. 📈
The small-cap early-stage biotech surged this week after announcing Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Its earnings also beat expectations, but it did miss on revenues. 🧫
Later in the week, the company priced a $125 million offering at $13.50 to take advantage of the market’s appetite for its shares. The cash will help it develop its pipeline of current and future drug candidates. 💸
$STOK is up 156.65% YTD.
Get In Touch
Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲
Help us deliver the best content possible by completing this brief survey. 📝
Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧
Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍
Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍
